Werewolf Therapeutics (HOWL) EBT (2020 - 2026)

Werewolf Therapeutics (HOWL) has reported EBT for 7 consecutive years, with $7.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT rose 138.68% year-over-year to $7.0 million in Q2 2026; TTM through Jun 2026 was -$33.8 million, a 53.85% increase from a year earlier, with the FY2025 full-year figure at -$62.8 million, up 12.2% from the prior year.
• EBT was $7.0 million for Q2 2026 at Werewolf Therapeutics, up from -$14.2 million in the prior quarter.
• Over five years, EBT peaked at $7.0 million in Q2 2026 and troughed at -$20.3 million in Q4 2024.
• A 5-year average of -$12.9 million and a median of -$14.5 million in 2022 frame the typical range for EBT.
• Across the five-year window, EBT tumbled 260.91% in 2024 and jumped 138.68% in 2026, its largest moves.
• Over 5 years, EBT stood at -$12.0 million in 2022, then increased by 0.02% to -$12.0 million in 2023, then plunged by 69.26% to -$20.3 million in 2024, then soared by 49.66% to -$10.2 million in 2025, then surged by 168.08% to $7.0 million in 2026.
• The last three EBT figures came in at $7.0 million (Q2 2026), -$14.2 million (Q1 2026), and -$10.2 million (Q4 2025), per Business Quant data.